MedPath

Measurement of coutaneous thickness under therapy with glucocorticoids of different strengh, calcineurininhibitor and basecreme, using different technical advices like ultrasound and optical coherencetomography.

Active, not recruiting
Conditions
- age 18-40 years- health volunteers- normal dermis- written accordance of the test person
MedDRA version: 14.0Level: LLTClassification code 10071104Term: Glucocorticoid therapySystem Organ Class: 10042613 - Surgical and medical procedures
MedDRA version: 14.0Level: LLTClassification code 10068183Term: Calcineurin inhibitor induced pain syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Equipment and Supplies [E07]
Registration Number
EUCTR2011-004953-17-DE
Lead Sponsor
Technical university Dresden
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

- age 18-40 years
- health volunteers
- normal dermis
- written accordance of the test person
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- pregnant or nursing woman,
- missing contraception,
- external or systemic therapy in the last 6 months with special drugs (Retinoids, Glucocorticoisteroids, Calcineurininhibitors,..)
- disease of the epidermis (atopic dermatitis, psoriasis, erythrodermie,...), skin disease who makes topical application of cremes impossible
- intensive UV-exposition or UV-therapy within the last 4 weeks or in trial,
- simultaneous participance in other clinical studies and participation in a second trial within the last 30 days
-hypersensitivity against Elidel®, Hydrogalen® Creme, Betagalen® Creme, Advantan® Creme, or Dermatop® Basecreme,
- disease with anticipate a therapy with Elidel®, Betagalen® Creme, Ecural® Fettcreme, Hydrogalen® Creme, Advantan® Creme or Dermatop® Basecreme,
- use of immunsuppressive drugs, or severe systemic disease,
- non-compliance,
-vaccination within the last 14 days

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath